Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    24687826 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Conditions: Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires
2 Active, not recruiting
Has Results
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: pazopanib;   Drug: sunitinib

Indicates status has not been verified in more than two years